Study of MR001 for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new drug, MR001, for people with triple-negative breast cancer that has come back or spread. It's for those who've already tried at least one type of treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer confirmed by a biopsy
- Your cancer has come back or spread after at least one prior treatment
- You have at least one tumor that can be measured on a scan
- You are able to take care of yourself (ECOG score 0 or 1)
- Your vital organs (like liver and kidneys) are working well enough
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ESG401, for people with triple-negative breast cancer that has come back or spread and cannot be removed by surgery. It compares ESG401 to standard chemotherapy options to see which works better.
This trial tests a new drug called BL-B01D1 combined with an immunotherapy (PD-1 antibody) against a standard chemo/immu-notherapy combination. It is for people with previously untreated, advanced triple-negative breast cancer whose tumors have a protein called PD-L1.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
This trial tests an experimental drug called QLC5513, either by itself or combined with another drug (QL1706), for people with triple-negative breast cancer that has continued to grow despite prior treatment. The goal is to see if this new approach can shrink tumors or slow the cancer's progression, and it might be an option if standard treatments have stopped working.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests a new drug called MR001, which is designed to help your immune system fight cancer, in people with advanced solid tumors that have not responded to other treatments. It may be an option if standard treatments have stopped working or caused too many side effects.
Hear when a new Triple-Negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.